DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts
Acta Neuropathologica · 2023-09 · 146 (3) · 543-545
DOI: 10.1007/s00401-023-02614-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 31.07.2023. Verfasst von Quynh T Tran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 250, Memphis, TN, 38105, USA. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Lebanese Syrian Associated Charities, National Cancer Institute.
Abstract (Originalsprache)
Atypical teratoid/rhabdoid tumors (ATRT) are malignant embryonal tumors, most often presenting in children under three years of age [7]. Three consensus ATRT molecular subtypes have been established, designated ATRT-SHH, ATRT-MYC, and ATRT-TYR [4, 5]. The ATRT-TYR group has been associated with better overall survival [3, 10]; whereas, patients with ATRT-SHH have inferior outcomes, largely attributable to an increased risk of metastasis [10]. Recently, Federico et al. analyzed a registry cohort of ATRT-SHH and reported three molecular subgroups designated ATRT-SHH 1A, 1B, and 2 [2]. While some novel molecular classes may represent important determinants of clinical outcome or surrogates of alternative driver mutations [6], others may reflect biologically driven differences, but lack clear clinical import. To validate the three ATRTSHH molecular subgroups and add insight into the clinical significance of these molecular classes, we evaluated the clinical features and outcome data for ATRT-SHH patients treated in St. Jude Children's Research Hospital (SJCRH) initiated multi-institutional clinical trials (n = 39): SJYC07, SJMB03, SJATRT, or in a consortium trial open at St. Jude: PBTC-001 (n = 2). Patients equivalently treated on nonprotocol treatment plan (NPTP) (n = 2) at St. Jude were also included where available. First, we validated three subgroups of ATRT-SHH using publicly available datasets containing ATRT-SHH tumors [1, 3, 4] (Supplemental Methods and Fig. S1). Next, we assigned consensus labels to SJCRH cases using a combination of unsupervised and semi-supervised methods [8–10] (Fig. S2). Consensus subgroup labels were reliably assigned to 41/43 cases, with 14 designated ATRT-SHH-1A, 11 ATRT-SHH-1B, and 16 ATRT-SHH-2 (Table S1). Analysis of the clinical data from these 41 patients supported the previous observations of subgroup-specific differences in tumor site (p = 0.005) [2]. We observed an enrichment of ATRTSHH-2 in the infratentorial compartment and ATRT-SHH-1 in the supratentorial compartment (Table S1). We also confirmed the previously observed difference in age at diagnosis with the ATRT-SHH-1B patients presenting at a median age of 3.5 years, compared to 1.1 years for both ATRT-SHH-1A and ATRT-SHH-2 (p = 0.008). No differences were identified with respect to gender or germline cancer predisposition among subgroups (Table S1). Next, we evaluated the patient outcomes for the thirty-six patients who enrolled on frontline trials or received NPTP equivalent to frontline protocols at diagnosis, including SJYC07 (n = 27), SJMB03 (n = 5), and PBTC-001 (n = 4). In contrast to the findings reported by Federico and colleagues [2], we did not observe differences in survival, including overall survival (OS) or progression-free survival (PFS) (Fig. 1a, b). We also evaluated ATRT-SHH subgroups for survival differences after considering metastatic status at presentation or with respect to post-recurrence survival but found no significant difference (data no shown). In summary, our findings validated reported substructure within the ATRT-SHH molecular group and confirmed Quynh T. Tran and Santhosh A. Upadhyaya have contributed equally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 250, Memphis, TN, 38105, USA.
- Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI, 48109, USA.
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
- Department of Hospitalist Medicine, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
- Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 250, Memphis, TN, 38105, USA. brent.orr@stjude.org.
Förderung
- NCI NIH HHS
- American Lebanese Syrian Associated Charities
- National Cancer Institute
Zitieren
APA
Tran, Q. T., Upadhyaya, S. A., Billups, C. A., Onar-Thomas, A., Alom, M. Z., Carey, S. S., Robinson, G. W., Ellison, D. W., Gajjar, A., & Orr, B. A. (2023). DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts. Acta Neuropathologica, 146(3), 543-545. https://doi.org/10.1007/s00401-023-02614-9
Vancouver
Tran QT, Upadhyaya SA, Billups CA, Onar-Thomas A, Alom MZ, Carey SS, et al. DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts. Acta Neuropathologica. 2023;146(3):543-545. doi:10.1007/s00401-023-02614-9
BibTeX
@article{Tran2023,
author = {Tran, Quynh T and Upadhyaya, Santhosh A and Billups, Catherine A and Onar-Thomas, Arzu and Alom, Md Zahangir and Carey, Steven S and Robinson, Giles W and Ellison, David W and Gajjar, Amar and Orr, Brent A},
title = {DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts},
journal = {Acta Neuropathologica},
year = {2023},
volume = {146},
number = {3},
pages = {543--545},
doi = {10.1007/s00401-023-02614-9}
}
EUVIMED